The Pharma Data

APRIL 4, 2023

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, can affect more than one body system simultaneously, and can occur at any time after starting treatment or after discontinuation of treatment.

Treatment

The Pharma Data

JULY 18, 2021

Clinical Data Supporting Approval Demonstrated Non-Inferior Immune Responses for the Serotypes Shared with PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F). VAXNEUVANCE Elicited Superior Immune Responses for Serotypes 3, 22F and 33F Compared to PCV13, Which Are Major Causes of Disease.

Disease

Codon

JANUARY 26, 2025

Over time, antigenic drift leads to new strains that partially or completely evade pre-existing immunity in the population. Jonas Salk in his Virus Research Laboratory (1954), together with assistant J.S. The vaccine must cross the mucosal barrier, ignite a robust immune response, yet not cause excessive inflammation.

Vaccine

Broad Institute

NOVEMBER 6, 2024

Kerry Reynolds: The first immune checkpoint inhibitor was FDA-approved in 2011 to treat melanoma, with nearly a dozen more ICIs approved for various cancers since then. That gives us a lot of hope, because we can think about targeting the inflamed organ that is failing without halting the immune response to the tumor.

Research

Codon

APRIL 4, 2025

.” An oil painting of Edward Jenner Adjuvant research experienced a huge boom in the early 20th century. Today, six adjuvants have been approved by the Food and Drug Administration (FDA), each triggering a different kind of immune response. A more pressing issue loomed.

Immune Response